Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPSMA-7.3 (18F) PET Imaging in Healthy Volunteers and Prostate Cancer Patients
NCT03995888Phase 1Completed
- Sponsor
- Blue Earth Diagnostics
- Start
- Jun 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of flotufolastat f 18 in prostate cancer (PCa) (2 arms), sponsored by Blue Earth Diagnostics. Primary endpoint: Treatment-emergent Adverse Events at 1 month. Started Jun 2019; status: completed.
02
Drugs
flotufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03995888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03995888.